Taking advantage of our newly developed screening conditions and using a collection of cancer patient specimens, large-scale phenotypical screens are run with collections of small molecules to identify hits that are effective on cancer cells as well as cancer stem cells.

Identity of the biomolecular targets affected by these hits is then elucidated using a multi-omic approach and facilitated by clustering the responsive specimens and analyzing their genetic and clinical characteristics.

Finally, synergistic interactions between these various hits/biomolecular targets is evaluated, leading to a comprehensive synergistic fingerprint for a specific type of cancer.